Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY 78.85
(-1.85%)
CNY 78.85
(-1.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 644.17 Million CNY | 393.54% |
| 2022 | 130.52 Million CNY | 107.25% |
| 2021 | 62.97 Million CNY | 120.76% |
| 2020 | -303.39 Million CNY | 24.24% |
| 2019 | -400.47 Million CNY | -311.19% |
| 2018 | -97.39 Million CNY | -150.15% |
| 2017 | -38.93 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 406.81 Million CNY | 16.2% |
| 2024 Q1 | 306.05 Million CNY | 30.93% |
| 2024 Q2 | 350.08 Million CNY | 14.39% |
| 2023 Q3 | 202.01 Million CNY | 16.41% |
| 2023 FY | 644.17 Million CNY | 393.54% |
| 2023 Q4 | 233.74 Million CNY | 15.71% |
| 2023 Q2 | 173.53 Million CNY | 397.56% |
| 2023 Q1 | 34.87 Million CNY | -54.46% |
| 2022 Q3 | 27.16 Million CNY | -45.05% |
| 2022 Q2 | 49.43 Million CNY | 318.55% |
| 2022 Q1 | -22.62 Million CNY | 80.61% |
| 2022 FY | 130.52 Million CNY | 107.25% |
| 2022 Q4 | 76.58 Million CNY | 181.91% |
| 2021 Q2 | -34.04 Million CNY | 23.15% |
| 2021 Q4 | -116.63 Million CNY | -154.69% |
| 2021 FY | 62.97 Million CNY | 120.76% |
| 2021 Q1 | -44.29 Million CNY | 58.08% |
| 2021 Q3 | 213.24 Million CNY | 726.41% |
| 2020 Q3 | -70.99 Million CNY | -4.05% |
| 2020 FY | -303.39 Million CNY | 24.24% |
| 2020 Q2 | -68.23 Million CNY | -4.01% |
| 2020 Q1 | -65.6 Million CNY | 56.03% |
| 2020 Q4 | -105.67 Million CNY | -48.84% |
| 2019 Q1 | -164.38 Million CNY | 0.0% |
| 2019 Q3 | -43.29 Million CNY | -6.6% |
| 2019 Q4 | -149.19 Million CNY | -244.57% |
| 2019 FY | -400.47 Million CNY | -311.19% |
| 2019 Q2 | -40.61 Million CNY | 75.29% |
| 2018 FY | -97.39 Million CNY | -150.15% |
| 2017 FY | -38.93 Million CNY | 0.0% |